Compare TVTX & CSTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TVTX | CSTM |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | France |
| Employees | N/A | 11500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.4B |
| IPO Year | 2013 | 2012 |
| Metric | TVTX | CSTM |
|---|---|---|
| Price | $40.41 | $29.47 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 4 |
| Target Price | ★ $40.46 | $30.75 |
| AVG Volume (30 Days) | ★ 2.2M | 2.1M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 92.89 | ★ 405.26 |
| EPS | N/A | ★ 1.92 |
| Revenue | N/A | ★ $8,449,000,000.00 |
| Revenue This Year | $43.88 | $21.46 |
| Revenue Next Year | $33.16 | $0.50 |
| P/E Ratio | ★ N/A | $15.45 |
| Revenue Growth | N/A | ★ 15.19 |
| 52 Week Low | $13.88 | $8.24 |
| 52 Week High | $43.31 | $31.20 |
| Indicator | TVTX | CSTM |
|---|---|---|
| Relative Strength Index (RSI) | 69.56 | 62.65 |
| Support Level | $32.62 | $13.79 |
| Resistance Level | $41.44 | N/A |
| Average True Range (ATR) | 2.17 | 1.36 |
| MACD | 1.26 | 0.26 |
| Stochastic Oscillator | 82.25 | 79.20 |
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
Constellium SE is engaged in the development, manufacture and sale of a broad range of high value-added specialty rolled and extruded aluminum products to the aerospace, space, defense, packaging, automotive, commercial transportation and general industrial end-markets. Its business model is to add value by converting aluminum into semi-fabricated and, in some instances, fully-fabricated alloyed aluminum products that meet stringent and performance-critical requirements from customers. It operates through three segments: Aerospace & Transportation Operating Segment, Packaging & Automotive Rolled Products Operating Segment, and Automotive Structures & Industry Operating Segment. It serves Aerospace, Packaging and Automotive and operates in the United States, France, Germany and others.